Stavudine (STV) is a pyrimidine nucleoside analogue used in the treatment of human immunodeficiency virus type 1 (HIV-1) infection. The rate-limiting step for the generation of the bioactive STV metabolite STV-triphosphate is the conversion of STV to its monophosphate derivative (1) (2) (3) (8) (9) (10) . In an attempt to overcome the dependence of STV on intracellular nucleoside kinase activation, we prepared STV-5Ј-(p-bromophenyl methoxyalaninyl phosphate) (stampidine [STAMP] ), a novel aryl phosphate derivative of STV, and structurally similar derivatives of STV, zidovudine (ZDV), and lamivudine (19) . The presence of a single para-bromine group in the phenyl moiety of STAMP contributes to its unique ability to undergo rapid hydrolysis, yielding the key active metabolite alaninyl-STV-monophosphate (4, 14, 17, 18) . In preliminary studies, we found that STAMP is substantially more potent than STV in inhibiting the replication of the laboratory HIV-1 strain HTLV IIIB in thymidine kinase-deficient T cells (19) . Balzarini et al. prepared similar compounds with the hypothesis that such lipophilic compounds would more easily enter HIV-infected cells, be metabolized in a thymidine kinase-independent fashion, and inhibit HIV replication in thymidine kinase-deficient cells such as macrophages (1) (2) (3) . The structure-activity relationships that determine the propensity of this class of compounds to undergo hydrolysis and inhibit HIV replication have recently been published (17) .
We previously investigated the in vivo pharmacokinetics, metabolism, toxicity, and antiretroviral activity of STAMP in rodent species (4) . In mice and rats, STAMP was very well tolerated, without any detectable acute or subacute toxicity at single intraperitoneal or oral bolus dose levels as high as 500 mg/kg of body weight (15) . Notably, daily administration of STAMP intraperitoneally or orally for up to 8 consecutive weeks was not associated with any detectable toxicity in mice or rats at cumulative dose levels as high as 6.4 g/kg (15) . STAMP exhibited potent in vivo anti-HIV activity in human peripheral blood lymphocyte-SCID mice at nontoxic dose levels (16) . In accordance with its safety profile in rodent species, a 4-week STAMP treatment course with twice-daily administration to dogs and cats of hard gelatin capsules containing STAMP at 25 to 100 mg/kg was very well tolerated at cumulative dose levels as high as 8. The purpose of the present study was to evaluate the antiretroviral activity of STAMP against primary clinical HIV-1 isolates. Phenotypic drug susceptibility studies of HIV-1 isolates and strains were performed by measuring the production of the p24 gag protein in PBMC from seronegative healthy volunteers in the presence of increasing concentrations of the a The results presented were obtained from a representative antiviral assay. The SE between individual antiviral assays was Ͻ10% of the average IC 50 . b All primary HIV-1 isolates except for 92BR019 were recovered from peripheral blood leukocytes-of HIV-infected individuals who had been treated with NRTI using previously described culture techniques (11, 13) . RT-MDR is an NRTI-resistant and nonnucleoside analog RT inhibitor-resistant laboratory strain of HIV-1, which was included as a control. HIV-1 RT-MDR-1/MT-2 (catalog no. 252) and 92BR019 (catalog no. 1778; envelope subtype B) were obtained through the NIH AIDS Research and Reference Reagent Program. The drug susceptibility assays were performed using PBMC, as described in the methods section.
c P Ͻ 0.0001 (for comparison between ZDV and STAMP; paired t test).
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anti-HIV agent using the quantitative Coulter HIV-1 p24 antigen enzyme immunoassay and HIV-1 p24 antigen kinetic standard (Beckman Coulter), as previously described (6, 13) . We used StatView in the calculation of the 50% inhibitory concentrations (IC 50 s) from each set of triplicate wells using the linearized form of an exponential equation (ln y ϭ ln b0 ϩ b1x; where y is percent inhibition and x is drug concentration). The inhibition constants were log 10 transformed to homogenize the variances within each group. Paired t tests were performed in order to test for differences between means of IC 50 s for STAMP and STV or ZDV across each viral strain. P values below 0.05 were deemed significant (JMP software; SAS). Currently available anti-HIV agents have been traditionally developed against subtype B HIV-1 strains, which are the predominant strains in the United States and Europe although worldwide the majority of HIV-infected individuals are infected with non-subtype B strains and the vast majority of new infections are caused by non-subtype B HIV-1 strains (7, 11) . Therefore, there is an urgent need to identify anti-HIV agents with potent activity against non-subtype B HIV-1. STAMP (mean IC 50 Ϯ standard error [SE] ϭ 1.7 Ϯ 0.7 nM) was 100-fold more potent than STV (IC 50 ϭ 240 Ϯ 7 nM; P Ͻ 0.0001 [paired t test on log 10 (Table 1) .
Contemporary antiretroviral treatment regimens employing combinations of drugs from at least two of the three classes of antiretroviral therapy-namely, nucleoside analog reverse transcriptase (RT) inhibitors (NRTI), nonnucleoside analog RT inhibitors, and protease inhibitors-exhibit a potent and sustained antiviral effect and confer consistent long-term viral suppression in patients with HIV infection (12) . However, the individual components of these combination regimens can select for drug-resistant viruses, and the emergence of antiviral drug resistance limits the clinical benefit of these drugs (11) . Patients failing on contemporary antiretroviral therapy programs constitute a reservoir of multidrug-resistant HIV that may limit treatment options in the future. The frequency of genotypic and phenotypic drug-resistant HIV is increasing among therapy-naïve HIV-infected seroconverters (5). Therefore, there also is an urgent need for new anti-HIV agents capable of inhibiting the replication of NRTI-resistant HIV. STAMP inhibited the in vitro replication of each one of 20 genotypically and phenotypically NRTI-resistant HIV-1 isolates carrying two to five thymidine analogue mutations associated with NRTI resistance at nanomolar concentrations, with an IC 50 (mean Ϯ SE) of 8.7 Ϯ 2.7 nM, whereas the IC 50 (mean Ϯ SE) of ZDV against the same isolates was 1.6 Ϯ 0.3 M (t value, 18.1, P Ͻ 0.0001 [paired t test on log 10 -transformed values]) (Table 2) . Notably, the phenotypically highly ZDV-resistant G190-6 and G704-2 isolates (ZDV IC 50 Ͼ10 M) carrying five thymidine analogue mutations were inhibited by STAMP, with average IC 50 s of 2.8 and 3.2 nM, respectively. These findings provide evidence that STAMP is a highly potent inhibitor of primary clinical HIV-1 isolates with a genotypic and/or phenotypic NRTI-resistant profile. The documented in vitro potency of STAMP against primary clinical HIV-1 isolates with genotypic and/or phenotypic NRTI resistance as well as against the non-B envelope subtype, together with a favorable toxicity profile in rodent (15, 16) and nonrodent (Uckun et al., submitted) animal species, and the in vivo antiretroviral activity of STAMP in HIV-infected human peripheral blood lymphocyte-SCID mice (16) as well as in FIV-infected cats (Uckun et al., submitted) warrant the further development of this promising new NRTI compound.
